SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001714899-23-000146
Filing Date
2023-11-07
Accepted
2023-11-07 16:05:45
Documents
60
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q dnli-20230930.htm   iXBRL 10-Q 1507555
2 EX-10.1 amendmenttodefinitivelrrk2.htm EX-10.1 55512
3 EX-31.1 exhibit311q32023.htm EX-31.1 9896
4 EX-31.2 exhibit312q32023.htm EX-31.2 9916
5 EX-32.1 exhibit321q32023.htm EX-32.1 5559
6 EX-32.2 exhibit322q32023.htm EX-32.2 5688
  Complete submission text file 0001714899-23-000146.txt   6206427

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20230930.xsd EX-101.SCH 39948
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnli-20230930_cal.xml EX-101.CAL 48668
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20230930_def.xml EX-101.DEF 200004
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20230930_lab.xml EX-101.LAB 562287
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20230930_pre.xml EX-101.PRE 363284
54 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20230930_htm.xml XML 756224
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38311 | Film No.: 231383665
SIC: 2836 Biological Products, (No Diagnostic Substances)